Literature DB >> 29713047

Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives: a 4-year follow-up study.

Alexandros Kasiakogias1, Costas Tsioufis2, Kyriakos Dimitriadis1, Dimitrios Konstantinidis1, Areti Koumelli1, Ioannis Leontsinis1, Eirini Andrikou1, Nikos Vogiatzakis1, Smaragdi Marinaki3, Dimitrios Petras4, Christos Fragoulis1, Konstantinos Konstantinou1, Vasilios Papademetriou5, Dimitrios Tousoulis1.   

Abstract

Data regarding the prognosis of resistant hypertension (RHTN) with respect to its severity is limited. We investigated the cardiovascular risk of severe RHTN in a prospective observational study. A cohort of 1700 hypertensive patient with treated uncontrolled HTN was followed for a mean period of 3.6 ± 1.8 years. At baseline, standard clinical and laboratory workup was performed, including testing for secondary causes of RHT where applicable. Three groups were identified depending on presence of RHTN (office-based uncontrolled HTN under at least three drugs including a diuretic) and levels of office systolic blood pressure (BP): 1187 patients (70%) without RHTN, 313 (18%) with not-severe RHTN (systolic BP < 160 mmHg) and 200 (12%) with severe RHTN (systolic BP ≥ 160 mmHg). Endpoint of interest was cardiovascular morbidity set as the composite of coronary heart disease and stroke. During follow-up, incidence rates of cardiovascular events per 1000 person-years were 7.1 cases in the non-RHTN group, 12.4 cases in the not-severe RHTN group and 18 cases in the severe RHTN group. Unadjusted analysis showed that compared to uncontrolled patients without RHTN, patients with not-severe RHTN exhibited a similar risk but patients with severe RHTN had a significantly higher risk, by 2.5 times (CI: 1.28-4.73, p = 0.007). Even after multivariate adjustment for established risk factors including BP levels and isolated systolic HTN, severe RHTN remained as an independent predictor of the cardiovascular outcome (OR: 2.30, CI: 1.00-5.29, p = 0.05). In conclusion, among treated yet uncontrolled hypertensive patients, severe RHTN exhibits a significantly higher cardiovascular risk indicating the need for prompt management.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29713047     DOI: 10.1038/s41371-018-0065-y

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  26 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

3.  Eligibility for renal denervation: experience at 11 European expert centers.

Authors:  Alexandre Persu; Yu Jin; Marie Baelen; Eva Vink; Willemien L Verloop; Bernhard Schmidt; Marie K Blicher; Francesca Severino; Grégoire Wuerzner; Alison Taylor; Antoinette Pechère-Bertschi; Fadi Jokhaji; Fadl Elmula M Fadl Elmula; Jan Rosa; Danuta Czarnecka; Georg Ehret; Thomas Kahan; Jean Renkin; Jiři Widimsky; Lotte Jacobs; Wilko Spiering; Michel Burnier; Patrick B Mark; Jan Menne; Michael H Olsen; Peter J Blankestijn; Sverre Kjeldsen; Michiel L Bots; Jan A Staessen
Journal:  Hypertension       Date:  2014-03-24       Impact factor: 10.190

Review 4.  Non-interventional management of resistant hypertension.

Authors:  Michael Doumas; Costas Tsioufis; Charles Faselis; Antonios Lazaridis; Haris Grassos; Vasilios Papademetriou
Journal:  World J Cardiol       Date:  2014-10-26

5.  Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.

Authors:  Alejandro de la Sierra; Julián Segura; José R Banegas; Manuel Gorostidi; Juan J de la Cruz; Pedro Armario; Anna Oliveras; Luis M Ruilope
Journal:  Hypertension       Date:  2011-03-28       Impact factor: 10.190

6.  Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.

Authors:  George Thomas; Dawei Xie; Hsiang-Yu Chen; Amanda H Anderson; Lawrence J Appel; Shirisha Bodana; Carolyn S Brecklin; Paul Drawz; John M Flack; Edgar R Miller; Susan P Steigerwalt; Raymond R Townsend; Matthew R Weir; Jackson T Wright; Mahboob Rahman
Journal:  Hypertension       Date:  2015-12-28       Impact factor: 10.190

7.  Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease.

Authors:  Sripal Bangalore; Rana Fayyad; Rachel Laskey; David A Demicco; Prakash Deedwania; John B Kostis; Franz H Messerli
Journal:  Am J Med       Date:  2013-11-07       Impact factor: 4.965

8.  Catheter-based renal denervation for resistant hypertension: Twenty-four month results of the EnligHTN I first-in-human study using a multi-electrode ablation system.

Authors:  Costas P Tsioufis; Vasilios Papademetriou; Kyriakos S Dimitriadis; Alexandros Kasiakogias; Dimitrios Tsiachris; Matthew I Worthley; Ajay R Sinhal; Derek P Chew; Ian T Meredith; Yuvi Malaiapan; Costas Thomopoulos; Ioannis Kallikazaros; Dimitrios Tousoulis; Stephen G Worthley
Journal:  Int J Cardiol       Date:  2015-08-07       Impact factor: 4.164

9.  Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension.

Authors:  John J Sim; Simran K Bhandari; Jiaxiao Shi; Kristi Reynolds; David A Calhoun; Kamyar Kalantar-Zadeh; Steven J Jacobsen
Journal:  Kidney Int       Date:  2015-05-06       Impact factor: 10.612

10.  Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.

Authors:  Anna Oliveras; Pedro Armario; Albert Clarà; Laia Sans-Atxer; Susana Vázquez; Julio Pascual; Alejandro De la Sierra
Journal:  J Hypertens       Date:  2016-09       Impact factor: 4.844

View more
  2 in total

Review 1.  Renal Artery Denervation for Hypertension.

Authors:  Lauren S Ranard; Rajesh V Swaminathan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-02-14

2.  Combined superposition effect of hypertension and dyslipidemia on left ventricular hypertrophy.

Authors:  Xueyao Zhang; Guangxiao Li; Chuning Shi; Dongyuan Zhang; Yingxian Sun
Journal:  Animal Model Exp Med       Date:  2022-06-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.